DD-CIP2 is a DNA damage inducer that triggers significant DNA damage, cell cycle arrest, and apoptosis by modulating DNA damage response pathways. It demonstrates notable antitumor efficacy without apparent toxicity at well-tolerated doses in vivo. Its exceptional cytotoxicity against a range of cancer cell lines from hematological and solid tumors is independent of their BRCA1/2 status. DD-CIP2 can be utilized in research on small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).

DD-CIP2 is capable of targeting various cancers, with specific IC50 values for different cancer cell lines: Jurkat cells at 12 nM, KARPASS422 at 12 nM, Raji at 11 nM, Daudi at 2 nM, TYK-nu at 9.3 nM, less than 10 nM for MDA-MB-436 cells, SU-DHL-5 at 0.8 nM, and MOLT-4 at 4.6 nM. In HEK293T cells, DD-CIP2 moderately increases PARP1 occupancy (EC50 = 42 nM). It induces PARP1-BRD4 interaction at 0.1-100 nM after 24 hours in HEK293T cells and reduces DNA damage in GLC16 and NCI-H82 cell lines. At 0.1-0.8 nM over 72 hours, DD-CIP2 demonstrates a dependency on PARP1-BRD4 binding in SU-DHL-5 cells. Additionally, a 10 µM concentration of DD-CIP2 for 24 hours impedes cell cycle progression in GLC16 cells.

In a human-derived small cell lung cancer xenograft mouse model, DD-CIP2 (20 mg/kg, intraperitoneal injection, administered once daily for 5 or 28 consecutive days) demonstrated potent antitumor activity with good tolerance and without noticeable systemic toxicity.